Consonance-Hfw Acq Corp (SRZN) Stock Price, Quote & News

Company Profile

Surrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat di...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 489 9000

Website: www.surrozen.com

Address:

171 Oyster Point Boulevard, Suite 400, South San Francisco, United States

Quantumup Mar. 19 at 12:24 PM

RBC Capital⬆️ $FDMT's PT to $35 from $32 and reiterated at Outperform after FDMT reported Q4 results. $OCUL $EYPT $SRZN REGN RHHBY KOD $OTSKY Here's what RBC Capital had to say in its note::: https://x.com/Quantumup1/status/2034605824538988952?s=20

0 · Reply

BuyoutBobby Mar. 19 at 9:27 AM

$SRZN kinda interesting so TCGX sold over 6 million Ocular Therapeutix shares in Q4 2025 while TCG terminated the related party deal with Surrozen in Q4 2025 and then started to buy a lot of shares of Surrozen. TCGX also started to buy shares of Surrozen in Q1 2026. So this seems like a bigger rotation of TCG from one ophthalmology player into another one. While Boehringer Ingelheim is looking for new ophthalmology drugs that perfectly fit our profile. And then new research is published that could indicate that Ocular Therapeutix drug axitinib(PDGF inhibition) could be worse than WNT drugs(PDGF activation).

1 · Reply

BuyoutBobby Mar. 18 at 10:26 PM

$SRZN TCG Crossover was a shareholder of Ocular Therapeutix with around 6 million shares but last reported on February 17 they published that they own 0 shares of OCUL now. Kinda interesting. They were loading Surrozen while selling Ocular.

0 · Reply

BuyoutBobby Mar. 18 at 2:37 PM

$SRZN i don't know if this is already known by Surrozen or Boehringer Ingelheim but this PDGFB signaling could be a huge thing. https://www.researchgate.net/publication/376389449_Role_of_endothelial_PDGFB_in_arterio-venous_malformations_pathogenesis

0 · Reply

BuyoutBobby Mar. 18 at 9:26 AM

$SRZN this looks like a publication of AntlerA for their WNT drug. It is possible that our WNT drugs have the same mechanism of action so this is very interesting. And in the picture what chatgpt thinks about it. https://www.researchgate.net/publication/402556042_A_FZD4LRP5_agonist_restores_pericyte_coverage_and_vascular_integrity_by_increasing_PDGFB_signaling

1 · Reply

Jw242 Mar. 16 at 11:13 PM

$SRZN column still loading

1 · Reply

Quantumup Mar. 16 at 12:48 PM

Guggenheim reiterated Top Pick $EYPT Buy; $68 $OCUL $REGN RHHBY $SRZN KOD $FDMT Here's what Guggenheim had to say in its note to investors: https://x.com/Quantumup1/status/2033524889840189801?s=20

0 · Reply

BuyoutBobby Mar. 15 at 6:48 PM

$SRZN they just published this interview from the OIS from last year. Some interesting things mentioned from the Boehringer Ingelheim guy. https://youtu.be/xb1typEm-2I?is=ZISQA9cTv63bS0Nc

1 · Reply

BuyoutBobby Mar. 14 at 7:04 PM

$SRZN this information from Re-Vana's website also strongly points to Regeneron and Roche as the potential partners for their approved drugs Eylea and Vabysmo.

0 · Reply

Nate1383 Mar. 13 at 3:23 PM

$SRZN not loving the price movement the last few days. I was hoping to see a climb over $30. At this point it seems like we are just waiting on buyout news to send it any higher

1 · Reply

Surrozen to Present at Upcoming Healthcare Investor Conference

Feb 23, 2026, 4:30 PM EST - 26 days ago

Surrozen Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Nov 25, 2025, 4:05 PM EST - 4 months ago

Surrozen to Present at Upcoming Healthcare Investor Conferences

Nov 7, 2025, 4:05 PM EST - 4 months ago

Surrozen Reports Third Quarter 2025 Financial Results and Provides Business Update

Sep 4, 2025, 4:15 PM EDT - 7 months ago

Surrozen Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Aug 8, 2025, 4:05 PM EDT - 8 months ago

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update

May 14, 2025, 8:30 AM EDT - 11 months ago

Surrozen Granted Patent from U.S. Patent and Trademark Office Directed to Antibody-Based Molecules Targeting Key Receptors in the Wnt Pathway

May 9, 2025, 4:05 PM EDT - 11 months ago

Surrozen Reports First Quarter 2025 Financial Results and Provides Business Update

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Surrozen Provides Fourth Quarter and Full Year 2024 Financial Results and Business Updates

Mar 24, 2025, 9:00 AM EDT - 1 year ago

Surrozen Announces an Oversubscribed $175 Million Private Placement of Securities to Focus on Selective Wnt Mimetic Therapeutics to Treat Serious Eye Diseases

Nov 6, 2024, 9:00 AM EST - 1 year ago

Surrozen Provides Third Quarter 2024 Financial Results and Business Update

Nov 4, 2024, 8:30 AM EST - 1 year ago

Surrozen and TCGFB, Inc. Announce Strategic Research Collaboration to Develop TGF-β Antibodies for Idiopathic Pulmonary Fibrosis

Sep 24, 2024, 8:30 AM EDT - 1 year ago

Surrozen Earns $10 Million Milestone Payment in Retinal Diseases Collaboration

Aug 12, 2024, 4:05 PM EDT - 1 year ago

Surrozen Provides Second Quarter 2024 Financial Results and Business Update

Jun 12, 2024, 8:30 AM EDT - 1 year ago

Surrozen Publishes Study in ‘eLife' Demonstrating the Promise of The Proprietary SWEETS Platform, a Unique Targeted Protein Degradation Technology, to Further Enhance Wnt Signaling

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Surrozen Presents Preliminary Results from Phase 1a Study of SZN-043 in Healthy Volunteers and Patients with a History of Liver Cirrhosis at the 2024 European Association for the Study of the Liver (EASL) in Milan

Jun 4, 2024, 8:30 AM EDT - 1 year ago

Surrozen Initiates Dosing of First Patient in Phase 1b Clinical Trial of SZN-043 for Severe Alcohol-Associated Hepatitis

May 9, 2024, 8:30 AM EDT - 2 years ago

Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting

May 8, 2024, 4:05 PM EDT - 2 years ago

Surrozen Provides First Quarter 2024 Financial Results and Business Update

Apr 3, 2024, 8:40 AM EDT - 2 years ago

Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis

Apr 1, 2024, 8:30 AM EDT - 2 years ago

Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043

Apr 1, 2024, 8:30 AM EDT - 2 years ago

Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules

Jan 18, 2024, 8:30 AM EST - 2 years ago

Surrozen Provides Corporate Update on Clinical Programs

Nov 8, 2023, 4:05 PM EST - 2 years ago

Surrozen Provides Third Quarter 2023 Financial Results

Aug 9, 2023, 4:05 PM EDT - 2 years ago

Surrozen Provides Second Quarter 2023 Financial Results

Jun 5, 2023, 8:30 AM EDT - 3 years ago

Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke

May 10, 2023, 4:05 PM EDT - 3 years ago

Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates

Apr 5, 2023, 8:30 AM EDT - 3 years ago

Surrozen Strengthens Board of Directors with the Appointment of Eric Bjerkholt

Mar 25, 2023, 10:02 AM EDT - 3 years ago

Surrozen, Inc. (SRZN) Q4 2022 Earnings Call Transcript

Mar 22, 2023, 4:01 PM EDT - 3 years ago

Surrozen Provides Fourth Quarter and Full Year 2022 Financial Results and Update on Clinical Pipeline and Corporate Progress

Mar 20, 2023, 4:30 PM EDT - 3 years ago

Surrozen To Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 22, 2023

Jan 4, 2023, 4:41 PM EST - 3 years ago

Surrozen to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 14, 2022, 4:30 PM EST - 3 years ago

Surrozen Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Oct 10, 2022, 8:00 AM EDT - 3 years ago

Surrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) Week

Oct 6, 2022, 8:00 AM EDT - 3 years ago

Surrozen Announces Strategic Partnership with Boehringer Ingelheim to Develop Wnt Agonist SZN-413 for People with Retinal Diseases

Sep 26, 2022, 8:00 AM EDT - 3 years ago

Surrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic Retinopathy

Aug 11, 2022, 8:00 AM EDT - 3 years ago

Surrozen Reports Second Quarter 2022 Financial Results

Jun 13, 2022, 8:00 AM EDT - 4 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic Hepatitis

May 24, 2022, 8:00 AM EDT - 4 years ago

Surrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)

May 18, 2022, 8:00 AM EDT - 4 years ago

Surrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative Colitis

May 16, 2022, 8:00 AM EDT - 4 years ago

Surrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Dise

May 11, 2022, 8:00 AM EDT - 4 years ago

Surrozen Reports First Quarter 2022 Financial Results

May 5, 2022, 8:00 AM EDT - 4 years ago

Surrozen to Present at the BofA Securities 2022 Healthcare Conference

May 2, 2022, 8:00 AM EDT - 4 years ago

Surrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Mar 24, 2022, 8:00 AM EDT - 4 years ago

Surrozen Reports Fourth Quarter and Full Year 2021 Financial Results

Jan 10, 2022, 8:00 AM EST - 4 years ago

Surrozen Announces Key 2022 Milestones for Lead Programs and Acceleration of Research Pipeline

Jan 5, 2022, 8:00 AM EST - 4 years ago

Surrozen to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

Nov 15, 2021, 4:00 PM EST - 4 years ago

Surrozen Reports Third Quarter 2021 Financial Results

Nov 15, 2021, 8:00 AM EST - 4 years ago

Surrozen to Present at The Piper Sandler 33rd Annual Healthcare Conference

Nov 15, 2021, 8:00 AM EST - 4 years ago

Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

Quantumup Mar. 19 at 12:24 PM

0 · Reply

BuyoutBobby Mar. 19 at 9:27 AM

1 · Reply

BuyoutBobby Mar. 18 at 10:26 PM

0 · Reply

BuyoutBobby Mar. 18 at 2:37 PM

0 · Reply

BuyoutBobby Mar. 18 at 9:26 AM

1 · Reply

Jw242 Mar. 16 at 11:13 PM

$SRZN column still loading

1 · Reply

Quantumup Mar. 16 at 12:48 PM

Guggenheim reiterated Top Pick $EYPT Buy; $68 $OCUL $REGN RHHBY $SRZN KOD $FDMT Here's what Guggenheim had to say in its note to investors: https://x.com/Quantumup1/status/2033524889840189801?s=20

0 · Reply

BuyoutBobby Mar. 15 at 6:48 PM

$SRZN they just published this interview from the OIS from last year. Some interesting things mentioned from the Boehringer Ingelheim guy. https://youtu.be/xb1typEm-2I?is=ZISQA9cTv63bS0Nc

1 · Reply

BuyoutBobby Mar. 14 at 7:04 PM

$SRZN this information from Re-Vana's website also strongly points to Regeneron and Roche as the potential partners for their approved drugs Eylea and Vabysmo.

0 · Reply

Nate1383 Mar. 13 at 3:23 PM

$SRZN not loving the price movement the last few days. I was hoping to see a climb over $30. At this point it seems like we are just waiting on buyout news to send it any higher

1 · Reply

BuyoutBobby Mar. 12 at 12:11 PM

$SRZN i think this is a nice overview of my due diligence:

1 · Reply

BuyoutBobby Mar. 11 at 10:30 PM

$SRZN head of quality gone since end of February

0 · Reply

BuyoutBobby Mar. 11 at 6:02 PM

$SRZN so TCG seems to be done buying with 1 month no buy. I will publish my due diligence tomorrow.

0 · Reply

BuyoutBobby Mar. 11 at 11:21 AM

$SRZN seems to be regarding the SZN-8141/8143 patents.

0 · Reply

Quantumup Mar. 9 at 1:14 PM

Mizuho $EYPT OP$36 $OCUL $REGN RHHBY KOD $SRZN $FDMT Mizuho said—EYPT reported 4Q results last week, with progress continuing for lead asset Duravyu, with (1) top-line P3 study data in wet AMD/wAMD still expected beginning in mid-2026, and (2) first patient dosing achieved in both P3 studies in diabetic macular edema/DME (with readouts expected in 2H27) That said, given recent reporting of first P3 data for competitor Ocular Therapeutix' (OCUL, NC) Axpaxli, investor debates remain highly active regarding potential differentiation between the two assets, and not surprisingly, this was the main focus on EYPT's 4Q call With this in mind, seeing (1) differentiated/improved efficacy and safety, (2) a better P3 trial design, and (3) a more straightforward path to approval and commercial uptake, we continue to believe Duravyu is better-positioned to become the best-in-class TKI-based maintenance therapy for wAMD As such, we stay Outperform-rated on EYPT, and view recent weakness as a buying opportunity

0 · Reply

Purch Mar. 6 at 6:09 PM

$SRZN This sure does get old. Lol

1 · Reply

BuyoutBobby Mar. 5 at 3:21 PM

$SRZN we know that big pharma is tracking every potential company that could be interesting to them so they always have an eye on this stock. What do you think will they do if they see all this behavior of TCG/Surrozen that looks like buyout preparations? And now they see the value of Surrozen increasing like this. They have no other choice but to engage Surrozen to find out if something is going on. They can't just hope that nobody else will buy Surrozen after insiders prepared everything for a buyout.

1 · Reply

Quantumup Mar. 5 at 1:09 PM

H.C. Wainwright⬆️ $EYPT to $30 and reiterated at Buy after the Co reported 4Q/FY finacial results/announced earlier this week that the Ph3 trials of DURAVYU in DME had dosed the first patients. $OCUL $REGN $RHHBY FDMT KOD $SRZN H.C. Wainwright said—Management noted that DURAVYU could potentially address both VEGF-mediated vascular leakage and IL-6 mediated inflammatory drivers of DME. Both COMO and CAPRI trials could report topline data in 2H27, according to management. In the wake of this update, we have included the Phase 3 DME program in our valuation and our estimated market value of the firm has increased to $2.51B, or approximately $30 per share. Therefore, we reiterate our Buy rating while raising our 12-month price target to $30 from $23 per share.

0 · Reply

Jw242 Mar. 4 at 8:36 PM

$SRZN 🤔

1 · Reply

Quantumup Mar. 4 at 8:05 PM

Chardan⬆️the PT on $EYPT to $29 from $27 and reiterated at a Buy rating. $OCUL $REGN RHHBY $SRZN KOD $FDMT Chardan said in its note—EyePoint reported 4Q25 financial results and provided updates on its Duravyu programs. The company ended the quarter with cash, cash equivalents, and marketable securities of $306 mm, with the projected operational runway into 4Q27. Updating our forward estimates raises our PT to $29 from $27. The next big catalyst for EyePoint is the Phase 3 Duravyu data from LUGANO and LUCIA trials in mid-2026. Our confidence in this program remains high, supported by robust Phase 2 data and the recently reported SOL-1 data from Ocular Therapeutics (Buy), which, we believe, provides further validation of the TKI MoA in wet AMD.

0 · Reply

OfficialStocktwitsUser Mar. 4 at 7:34 PM

$SRZN RSI: 67.11, MACD: 1.6701 Vol: 2.12, MA20: 25.39, MA50: 22.67 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

BuyoutBobby Mar. 4 at 2:10 PM

$SRZN TD Cowen 46th Annual Healthcare Conference today.

0 · Reply

Market Cap	220.11M
Revenue (ttm)	10.66M
Net Income (ttm)	-63.56M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-596.25%
Debt to Equity Ratio	0.00

Volume	66,300
Avg Vol	110,476
Day's Range	N/A - N/A
Shares Out	8.57M
Stochastic %K	28%
Beta	0.53
Analysts	Strong Sell
Price Target	$37.50